CJC-1295

CJC-1295 is a synthetic GHRH analog that binds pituitary somatotrophs to amplify natural growth hormone pulses. It is under FDA reclassification review as part of the 14-peptide RFK Jr. initiative and is most commonly stacked with ipamorelin for anti-aging and body composition use.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pituitary somatotrophs to secrete growth hormone. The compound exists in two pharmacologically distinct forms: CJC-1295 with DAC (Drug Affinity Complex), which binds covalently to serum albumin and achieves a half-life of 5.8-8.1 days, and CJC-1295 without DAC — also marketed as Modified GRF 1-29 or Mod GRF 1-29 — which behaves as a standard short-acting GHRH analog with a half-life of 30 minutes to 2 hours. Understanding this distinction is essential because the two variants have fundamentally different pharmacokinetic profiles and therefore different clinical utility.

CJC-1295's underlying sequence is derived from the first 29 amino acids of native human GHRH (GHRH 1-29 = Sermorelin), but with four substitutions that confer stability against plasma dipeptidylpeptidase IV (DPP-IV) degradation. These substitutions — at positions 2, 8, 15, and 27 — extend the active half-life of the no-DAC form from the ~3-minute plasma lifetime of native GHRH(1-29) to approximately 30 minutes. When the DAC modification (a maleimidopropionic acid lysine moiety) is added, the peptide reacts in vivo with cysteine-34 on serum albumin, turning albumin into a slow-release reservoir that releases active peptide over days.

The two forms serve different research and clinical goals. CJC-1295 with DAC — typically dosed once weekly — produces a prolonged "GH bleed": mean plasma GH increases 2-10-fold for 6 or more consecutive days, with mean IGF-1 rising 1.5-3-fold for 9-11 days after a single injection (Teichman et al., JCEM, 2006). CJC-1295 without DAC is instead stacked with a GH-releasing peptide like ipamorelin to produce large, physiological GH pulses — the short half-life times the peak with each injection, allowing pulsatility to be preserved and controlled. This combinational approach is widely used in integrative medicine and anti-aging practice, where mimicking natural GH rhythms is preferred over sustained tonic elevation.

CJC-1295 has attracted interest for applications in muscle preservation, fat loss, recovery from injury, and slow-wave sleep enhancement. Its mechanism through the GHRH receptor (GHRHR) on pituitary somatotrophs means it operates within the hypothalamic-pituitary-somatotropic axis, and unlike exogenous recombinant human GH (rhGH), it relies on the pituitary's own secretory machinery — preserving negative feedback via somatostatin and IGF-1 and thereby reducing the risk of pituitary desensitization or systemic GH excess. CJC-1295 has no FDA-approved indication but is among the peptides under consideration in the ongoing reclassification review of compounding pharmacy-accessible peptides.

CJC-1295 binds with high affinity to the pituitary GHRH receptor (GHRHR), a Gs-protein-coupled receptor. Agonist binding activates adenylyl cyclase, elevating intracellular cAMP in somatotroph cells. cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). CREB activation upregulates transcription of the GH gene (GH1) and simultaneously stimulates the secretory machinery responsible for releasing pre-synthesized GH-containing vesicles. The cAMP/PKA cascade also opens voltage-gated calcium channels on somatotroph membranes, providing additional Ca²⁺ influx that triggers exocytosis. The result is a dose-dependent pulse of GH secretion that begins within minutes and — in the case of CJC-1295 without DAC — peaks and resolves over 2-3 hours.

The DAC modification fundamentally changes this pharmacokinetic picture. The maleimidopropionic acid conjugate on the lysine residue at position 29 is reactive toward free thiols in plasma, selectively forming a covalent thioether bond with the Cys-34 residue of human serum albumin within minutes of subcutaneous injection. Because albumin has a half-life of approximately 19 days, the CJC-1295-albumin conjugate is released gradually as the body naturally turns over albumin. Active peptide leaches off at a rate that maintains plasma concentrations above the GH-stimulating threshold for approximately 8-10 days per injection. The consequence is a sustained "GH bleed" — not a single pulse but a continuous, low-amplitude increase in GH secretion superimposed on the pituitary's remaining pulsatile rhythms.

Pulsatile GH secretion is preserved even during CJC-1295 DAC administration because the pituitary retains responsiveness to hypothalamic regulatory inputs. A 2006 study by Jetté et al. (Endocrinology, 2006) demonstrated that pulsatile GH secretion persists with elevated amplitude when subjects receive chronic CJC-1295 stimulation. This is mechanistically important: somatostatin is released by the hypothalamus in a separate pulsatile pattern that creates the GH troughs needed for normal physiological feedback. CJC-1295 amplifies each GHRH-driven peak without completely obliterating the troughs, distinguishing it from direct rhGH injection in terms of physiological fidelity.

Downstream, sustained or amplified GH elevation drives hepatic IGF-1 production. IGF-1 acts as the primary anabolic mediator: it binds the IGF-1 receptor (IGF1R), a receptor tyrosine kinase, activating PI3K/Akt/mTOR (protein synthesis) and MEK/ERK (proliferation) cascades in skeletal muscle, bone, and connective tissue. GH independently activates JAK2/STAT5 in liver and muscle. The net downstream biology — lean mass accretion, lipolysis, collagen synthesis, and bone matrix deposition — is qualitatively the same whether driven by CJC-1295 with DAC, without DAC, or by rhGH directly; the difference lies in the kinetics and the degree to which normal pituitary feedback mechanisms are preserved.

The pivotal human pharmacology study for CJC-1295 was published by Teichman et al. in the Journal of Clinical Endocrinology and Metabolism (JCEM) in 2006. This randomized, placebo-controlled, double-blind, ascending-dose trial enrolled healthy adults aged 21-61 years and administered single subcutaneous doses of CJC-1295 with DAC ranging from 30 to 120 µg/kg. After a single injection, mean plasma GH concentrations increased by 2- to 10-fold relative to baseline and remained elevated for 6 or more consecutive days. Mean plasma IGF-1 rose by 1.5- to 3-fold for 9-11 days. The estimated half-life of CJC-1295 was 5.8-8.1 days. In the multi-dose arm of the study, mean IGF-1 levels remained above baseline for up to 28 days. Subcutaneous administration was well tolerated, particularly at doses of 30 and 60 µg/kg, with the most common adverse event being transient injection site erythema.

The question of whether continuous GH stimulation with CJC-1295 DAC obliterates physiological pulsatility was addressed by Jetté et al. (Endocrinology, 2006) using a rat model. Despite sustained GHRH receptor stimulation, pituitary somatotrophs maintained pulsatile GH release — with elevated pulse amplitude compared to controls. Somatostatin rhythms were sufficient to generate residual GH troughs. These data were important for establishing that the DAC formulation does not create a flat, pharmacological GH elevation analogous to rhGH injection, but rather amplifies a pattern that retains some physiological character.

Studies comparing the two CJC-1295 forms highlight a fundamental design tradeoff. CJC-1295 without DAC (Mod GRF 1-29), with its 30-minute to 2-hour half-life, is designed to be co-administered with a GH secretagogue such as ipamorelin, where their simultaneous presence at the pituitary produces a synergistic GH pulse before both clear. The 1999 study by Bowers demonstrating synergistic GH output from combined GHRH + GHRP administration underpins the modern CJC-1295 / ipamorelin stacking rationale. GH output from the combination is reported to be 2-3× greater than additive, reflecting the complementary second-messenger cascades (cAMP via GHRHR and Ca²⁺/IP₃ via GHS-R1a) converging on the same secretory granules.

A 2009 study by Asada et al. (Growth Horm IGF Res) examined the downstream serum proteome changes produced by CJC-1295 DAC administration in healthy adults, finding changes in proteins related to lipid metabolism, insulin signaling, and muscle protein turnover consistent with GH/IGF-1 axis activation. Insulin sensitivity data from this study were within normal range at the doses tested, though longer-duration, higher-dose regimens have not been characterized in human trials.

The primary evidence gap is identical to ipamorelin: large randomized controlled trials measuring body composition, bone density, or functional outcomes over 6-12 months in defined patient populations do not exist. CJC-1295's robust human pharmacokinetic data from Teichman et al. are among the highest-quality published for any GH-releasing peptide outside of formal drug development, but efficacy and long-term safety trials remain unpublished. Regulatory trajectory — CJC-1295 is included in FDA compounding pharmacy reclassification discussions — will likely determine whether such trials proceed.[1][2][3][4][5]

Peptides commonly paired with CJC-1295 for synergistic effects.